Maze Therapeutics (NASDAQ:MAZE) Price Target Raised to $46.00 at BTIG Research

Maze Therapeutics (NASDAQ:MAZE) had its price target boosted by equities researchers at BTIG Research from $37.00 to $46.00 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. BTIG Research’s price target suggests a potential upside of 12.00% from the company’s current price.

MAZE has been the topic of several other reports. Wells Fargo & Company initiated coverage on shares of Maze Therapeutics in a research note on Thursday, December 4th. They set an “overweight” rating and a $55.00 price objective on the stock. HC Wainwright boosted their price target on Maze Therapeutics from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, December 3rd. Wall Street Zen raised Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 13th. Lifesci Capital raised Maze Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. Finally, JPMorgan Chase & Co. increased their price target on Maze Therapeutics from $27.00 to $37.00 and gave the company an “overweight” rating in a research note on Monday, September 29th. Three analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $44.50.

Maze Therapeutics Price Performance

MAZE stock traded up $1.26 during mid-day trading on Friday, reaching $41.07. The company had a trading volume of 72,607 shares, compared to its average volume of 296,719. The company has a market capitalization of $1.98 billion and a price-to-earnings ratio of -1.97. Maze Therapeutics has a 52 week low of $6.71 and a 52 week high of $43.29. The stock has a 50 day simple moving average of $38.46 and a two-hundred day simple moving average of $26.66.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.74) by $0.08.

Insiders Place Their Bets

In related news, SVP Amy Bachrodt sold 10,000 shares of the firm’s stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $40.58, for a total transaction of $405,800.00. Following the transaction, the senior vice president directly owned 12,965 shares of the company’s stock, valued at approximately $526,119.70. This trade represents a 43.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CMO Harold Bernstein sold 45,000 shares of the business’s stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $40.56, for a total transaction of $1,825,200.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 167,500 shares of company stock worth $6,774,667 in the last 90 days.

Institutional Investors Weigh In On Maze Therapeutics

Several institutional investors have recently made changes to their positions in MAZE. Ameritas Investment Partners Inc. grew its position in Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after acquiring an additional 738 shares during the last quarter. Russell Investments Group Ltd. lifted its stake in Maze Therapeutics by 947.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after purchasing an additional 1,725 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in Maze Therapeutics in the third quarter valued at approximately $52,000. CWM LLC bought a new stake in shares of Maze Therapeutics during the second quarter worth $28,000. Finally, Legal & General Group Plc increased its holdings in shares of Maze Therapeutics by 387.0% during the second quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock worth $52,000 after buying an additional 3,371 shares in the last quarter.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.